Single Convention on Narcotic Drugs


The Single Convention on Narcotic Drugs, 1961 is an international treaty that controls activities involving specific narcotic drugs and lays down a system of regulations for their medical and scientific uses, concluded under the auspices of the United Nations. The convention also establishes the International Narcotics Control Board.
The Single Convention was adopted in 1961 and amended in 1972. As of 2022, the Single Convention as amended has been ratified by 186 countries. The convention has since been supplemented by the 1971 Convention on Psychotropic Substances, which controls LSD, MDMA, and other psychoactive pharmaceuticals, and the 1988 United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances; the three conventions establish the legal framework for international drug control.

Ratification

The Single Convention as amended in 1972 had been ratified or acceded to by 186 states. Only Chad remained party to the original 1961 Convention in its unamended form. The Cook Islands, Equatorial Guinea, Kiribati, Nauru, Niue, Samoa, South Sudan, Timor-Leste, Tuvalu, and Vanuatu are not parties.
Since the Single Convention is not self-executing, parties must enact legislation to carry out its provisions, and the UNODC works with countries' legislatures to ensure compliance.

History

The League of Nations adopted several drug control treaties prior to World War II, such as the First and Second International Opium Convention, and International Convention relating to Dangerous Drugs specifying uniform controls on addictive drugs such as cocaine and opium, and its derivatives. However, the lists of controlled substances were fixed in the treaties' text. Consequently, it was necessary to periodically amend or supersede the conventions with the introduction of new treaties to keep up with advances in chemistry. According to a 1954 interview with United States Commissioner of Narcotics Harry J. Anslinger, the cumbersome process of conference and state-by-state ratification could take many decades.
A Senate of Canada committee reported: "The work of consolidating the existing international drug control treaties into one instrument began in 1948, but it was 1961 before an acceptable third draft was ready." That year, the UN Economic and Social Council convened a plenipotentiary conference of 73 nations for the adoption of a single convention on narcotic drugs. That meeting was known as the United Nations Conference on Narcotic Drugs. The participating states organized themselves into five distinct caucuses:Organic states group: As producers of the organic raw materials for most of the global drug supply, these countries had been the traditional focus of international drug control efforts. They were open to socio-cultural drug use, having lived with it for centuries or rather millennia. While India, Turkey, Pakistan and Burma took the lead, the group also included the coca-producing states of Indonesia and the Andean region of South America, the opium- and cannabis-producing countries of South and Southeast Asia, and the cannabis-producing states in the Horn of Africa. They favored weak controls because existing restrictions on production and export had directly affected large segments of their domestic population and industry. They supported national control efforts based on local conditions and were wary of strong international control bodies under the UN. Essentially powerless to fight the prohibition philosophy directly, they could only force a compromise by working together to dilute the treaty language with exceptions, loopholes and deferrals. They also sought development aid to compensate for losses caused by strict controls.Manufacturing states group: This group included primarily Western industrialized nations, the key players being the United States, the United Kingdom, Canada, Switzerland, the Netherlands, West Germany, and Japan. Having no cultural affinity for organic drug use and being faced with the effects that drug abuse was having on their citizens, they advocated stringent controls on the production of organic raw materials and on illicit trafficking. As the principal manufacturers of synthetic psychotropics, and backed by a determined industry lobby, they forcefully opposed undue restrictions on medical research or the production and distribution of manufactured drugs. They favored strong supranational control bodies as long as they continued to exercise de facto control over such bodies. According to W.B. McAllister's Drug Diplomacy in the Twentieth Century, their strategy was essentially to "shift as much of the regulatory burden as possible to the raw-material-producing states while retaining as much of their own freedom as possible."Strict control group: These were essentially non-producing and non-manufacturing states with no direct economic stake in the drug trade. The key members were France, Sweden, Brazil, and the Republic of China. Most of the states in this group were culturally opposed to drug use and suffered from abuse problems. They favored restricting drug use to medical and scientific purposes and were willing to sacrifice a degree of national sovereignty to ensure the effectiveness of supranational control bodies. They were forced to moderate their demands to secure the widest possible agreement.Weak control group: This group was led by the Soviet Union and often included its allies in Europe, Asia and Africa. They considered drug control a purely internal issue and adamantly opposed any intrusion on national sovereignty, such as independent inspections. With little interest in the drug trade and minimal domestic abuse problems, they refused to give excessive power to any supranational body, especially over internal decision-making.Neutral group: This was a diverse group including most of the African countries, Central America, sub-Andean South America, Luxembourg and the Vatican. They had no strong interest in the issue apart from ensuring their own access to sufficient drug supplies. Some voted with political blocs, others were willing to trade votes, and others were truly neutral and could go either way on the control issue depending on the persuasive power of the arguments presented. In general, they supported compromise with a view to obtaining the broadest possible agreement.
These competing interests, after more than eight weeks of negotiations, finally produced a compromise treaty. Several controls were weakened; for instance, the proposed mandatory embargoes on nations failing to comply with the treaty became recommendations. The 1953 New York Opium Protocol, which had not yet entered into force, limited opium production to seven countries; the Single Convention lifted that restriction, but instituted other regulations and put the International Narcotics Control Board in charge of monitoring their enforcement. A compromise was also struck that allowed heroin and some other drugs classified as particularly dangerous to escape absolute prohibition.
The Single Convention created four Schedules of controlled substances and a process for adding new substances to the Schedules without amending the treaty. The Schedules were designed to have significantly stricter regulations than the two drug "Groups" established by predecessor treaties. For the first time, cannabis was added to the list of internationally controlled drugs. In fact, regulations on the cannabis plant – as well as the opium poppy, the coca bush, poppy straw and cannabis tops – were embedded in the text of the treaty, making it impossible to deregulate them through the normal Scheduling process. A 1962 issue of the Commission on Narcotic Drugs' Bulletin on Narcotics proudly announced that "after a definite transitional period, all non-medical use of narcotic drugs, such as opium smoking, opium eating, consumption of cannabis and chewing of coca leaves, will be outlawed everywhere. This is a goal which workers in international narcotics control all over the world have striven to achieve for half a century."
A 3 August 1962, Economic and Social Council resolution ordered the publication of the Commentary on the Single Convention on Narcotic Drugs. The legal commentary was written by the United Nations Secretary-General staff member Adolf Lande, the former Secretary of the Permanent Central Narcotics Board and Drug Supervisory Body, operating under a mandate to give "an interpretation of the provisions of the Convention in the light of the relevant conference proceedings and other material." The Commentary contains the Single Convention's legislative history and can be a valuable aid to interpreting the treaty, when used alongside contemporaneous sources such as the Official Records.
The Single Convention entered into force on 13 December 1964, having met Article 41's requirement of 40 ratifications. As of 1 January 2005, 180 states were Parties to the treaty. Others, such as Cambodia, have committed to becoming Parties.
On 21 May 1971, the UN Economic and Social Council called a conference of plenipotentiaries to consider amendments to the Single Convention. The conference met at the United Nations Office at Geneva from 6 to 24 March 1972, producing the 1972 Protocol Amending the Single Convention on Narcotic Drugs. The amendments entered into force on 8 August 1975.
On 11 November 1990, mechanisms for enforcing the Single Convention were expanded significantly by the entry into force of the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, which had been signed at Vienna on 20 December 1988. The Preamble to this treaty acknowledges the inadequacy of the Single Convention's controls to stop "steadily increasing inroads into various social groups made by illicit traffic in narcotic drugs and psychotropic substances". The new treaty focuses on stopping organized crime by providing for international cooperation in apprehending and convicting gangsters and starving them of funds through forfeiture, asset freezing, and other methods. It also establishes a system for placing precursors to Scheduled drugs under international control. Some non-Parties to the Single Convention, such as Andorra, belong to this treaty and thus are still under the international drug control regime.

Provisions

Purposes

Medical and scientific purposes

The Single Convention repeatedly affirms the importance of medical use of controlled substances. The Preamble notes that "the medical use of narcotic drugs continues to be indispensable for the relief of pain and suffering and that adequate provision must be made to ensure the availability of narcotic drugs for such purposes". Articles 1, 2, 4, 9, 12, 19, and 49 contain provisions relating to "medical and scientific" use of controlled substances. In almost all cases, parties are permitted to allow dispensation and use of controlled substances under a prescription, subject to record-keeping requirements and other restrictions.
The Single Convention unambiguously condemns "abuse of drugs", even stating that "addiction to narcotic drugs constitutes a serious evil for the individual and is fraught with social and economic danger to mankind". It aims to limit the global production of controlled drugs to an amount adequate to satisfy the estimated global demand for medical and scientific purposes without producing a surplus that could lead to diversion and addiction. Article 4 requires nations to take legislative and administrative measures necessary to limit production, trade, use and possession of drugs to medical and scientific purposes. Article 49 allowed countries to temporarily permit coca leaf chewing, opium smoking, and other traditional drug uses at the time of signature, ratification, or accession, but provides that countries opting to do so would be required to phase out these and other traditional uses by specific dates after the convention came into force.
As of 2025, 138 substances are controlled under the Single Convention.

Non-medical and non-scientific purposes

The Single Convention contains specific exemptions for drugs used for non-medical and non-scientific purposes. The most broad of these is Article 2(9), which permits a country to unilaterally exempt a drug that is commonly used in industry from nearly all control requirements of the convention, provided that the country ensures by appropriate means that the drug is not liable to be abused or have ill effects, and that the country include the quantity of the drug exempted under this article in its annual statistical submissions.
Other non-medical purposes that convention does not require the Parties to prohibit include the manufacture of substances not covered by the convention, the use of coca leaf as a flavoring agent, and the cultivation of the cannabis plant for industrial purposes.
Some analysts suggest the "recreational use" of drugs is part of the "other than medical and scientific purposes," and therefore exempt from the measure of control of the convention, which are limited to "medical and scientific purposes;" others analysts have, however, suggested that "other than medical and scientific purposes" does not encompass recreational use.
Malta seem to have followed article 2 paragraph 9 of the Single Convention, which allows to regulate the use of drugs, other than medical and scientific, in the context of industry.

Penal provisions

As scholars note: "although formally binding, the penal provisions prove remarkably soft" and, as explained in the Commentary on the Single Convention, they are "rather vague, and escape clauses for the benefit of those Governments to which even such vague norms would be unacceptable."
Article 36 requires Parties to adopt measures against "cultivation, production, manufacture, extraction, preparation, possession, offering, offering for sale, distribution, purchase, sale, delivery on any terms whatsoever, brokerage, dispatch, dispatch in transit, transport, importation and exportation of drugs contrary to the provisions of this Convention," as well as "ntentional participation in, conspiracy to commit and attempts to commit, any of such offences, and preparatory acts and financial operations in connexion with the offences referred to in this article", but it does not directly require criminalization of all the above; it states only in the cases of serious offences that they "shall be liable to adequate punishment particularly by imprisonment or other penalties of deprivation of liberty."
The Article also provides for extradition of drug offenders, although a Party has a right to refuse to extradite a suspect if "competent authorities consider that the offense is not sufficiently serious." A 1972 amendment to the Article grants nations the discretion to substitute "treatment, education, after-care, rehabilitation and social reintegration" for criminal penalties if the offender is a drug abuser. The Single Convention requires Parties to enact criminal laws for illicit drug-related activities, but does not clearly mandate their uniform enforcement.
Drug enforcement varies widely between nations. Many European countries, including the United Kingdom, Germany, and, most famously, the Netherlands, do not prosecute all petty drug offenses. Dutch coffee shops are allowed to sell small amounts of cannabis to consumers. However, the Ministry of Health, Welfare and Sport's report, Drugs Policy in the Netherlands, notes that large-scale "roduction and trafficking are dealt with severely under the criminal law, in accordance with the UN Single Convention. Each year the Public Prosecutions Department deals with an average of 10,000 cases involving infringements of the Opium Act." Some of the most severe penalties for drug trafficking are handed down in certain Asian countries, such as Malaysia, which mandate capital punishment for offenses involving amounts over a certain threshold. Singapore mandates the death penalty for trafficking in 15 g of heroin, 30 g of cocaine or 500 g of cannabis. Most nations, such as France and the United States, find a middle ground, imposing a spectrum of sanctions ranging from probation to life imprisonment for drug offenses.
The Single Convention's penal provisions frequently begin with clauses such as "Subject to its constitutional limitations, each Party shall..." Thus, if a nation's constitution prohibited instituting the criminal penalties called for by the Single Convention, those provisions would not be binding on that country.

Possession for personal use

It is unclear whether or not the treaty requires criminalization of drug possession for personal use. The treaty's language is ambiguous, and a ruling by the International Court of Justice would probably be required to settle the matter decisively. However, several commissions have attempted to tackle the question. With the exception of the Le Dain Commission, most have found that states are allowed to legalize possession for personal use.
The Canadian Le Dain Commission of Inquiry into the Non-Medical Use of Drugs' 1972 report cites circumstantial evidence suggesting that states must prohibit possession for personal use:
However, LeDain himself concludes
The Canadian Department of National Health and Welfare's 1979 report, The Single Convention and Its Implications for Canadian Cannabis Policy, counters with circumstantial evidence to the contrary:
The Sackville Commission of South Australia concluded in 1978 that:
The American Shafer Commission reached a similar conclusion in 1972, finding "that the word 'possession' in Article 36 refers not to possession for personal use but to Possession as a link in illicit trafficking."
The Canadian Department of National Health and Welfare report cites the Commentary itself in backing up its interpretation:
The Bulletin on Narcotics attempted to tackle the question in 1977:

Regulation of cannabis and hemp cultivation

The Single Convention places generally the same restrictions on cannabis cultivation that it does on opium cultivation, although there are cannabis-specific dispositions.
Article 23 and Article 28 require each Party to establish a government agency to control cultivation for medical and scientific purposes. Cultivators must deliver their total crop to the agency, which must purchase and take physical possession of them within four months after the end of harvest. The agency then has the exclusive right of "importing, exporting, wholesale trading and maintaining stocks other than those held by manufacturers."In the United States, the National Institute on Drug Abuse fulfills that function. NIDA administers a contract with the University of Mississippi to grow a 1.5 acre crop of cannabis every other year; that supply comprises the only licit source of cannabis for medical and research purposes in the United States. Similarly, in 2000, Prairie Plant Systems was awarded a five-year contract to grow cannabis in the Flin Flon mine for Health Canada, that nation's licit cannabis cultivation authority.
Article 28 specifically excludes the cultivation of industrial hemp from these regulations, stating:
"This Convention shall not apply to the cultivation of the cannabis plant exclusively for industrial purposes or horticultural purposes."
In addition, article 2 permits countries to exempt the cannabis tops and resin obtained from hemp grown for industrial purposes from many provisions of the convention.
Once on a path to reduction, there are now an increasing number of countries worldwide which are returning to hemp cultivation, often a traditional crop in various regions of the world, according to a report of the United Nations Conference on Trade and Development.

Drugs and preparations under control

The treaty updated the Paris Convention of 13 July 1931, to include the vast number of synthetic opioids invented in the intervening 30 years and to add a mechanism for more easily including new ones. From 1931 to 1961, most of the families of synthetic opioids had been developed, including drugs related to methadone, pethidine, morphinans, and dextromoramide. Research on fentanyls and piritramide was also nearing fruition at that point.
Earlier treaties had only controlled opium, coca, and derivatives such as morphine, heroin, and cocaine. The Single Convention, adopted in 1961, consolidated those treaties and broadened their scope to include cannabis and other substances with effects similar to drugs already covered. The Commission on Narcotic Drugs and the World Health Organization were empowered to add, remove, and transfer drugs among the treaty's four schedules of controlled substances. The International Narcotics Control Board was put in overall control of drug production, international trade, and dispensation. The United Nations Office on Drugs and Crime was delegated the Board's daily monitoring of each country and working with national authorities to ensure compliance with the Single Convention. This treaty has since been supplemented by the Convention on Psychotropic Substances, which controls LSD, MDMA, and other psychoactive pharmaceuticals, and the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, which strengthens provisions against money laundering and other drug-related offenses.

Schedules

The Single Convention's Schedules of drugs range from most restrictive to least restrictive, in this order: Schedule IV, Schedule I, Schedule II, Schedule III. The list of drugs initially controlled was annexed to the treaty. Article 3 states that for a drug to be placed in a Schedule, the World Health Organization must make the findings required for that Schedule, to wit:Schedule I – The substance is liable to similar abuse and productive of similar ill effects as the drugs already in Schedule I or Schedule II, or is convertible into a drug.Schedule II – The substance is liable to similar abuse and productive of similar ill effects as the drugs already in Schedule I or Schedule II, or is convertible into a drug.Schedule III – The preparation, because of the substances which it contains, is not liable to abuse and cannot produce ill effects; and the drug therein is not readily recoverable.Schedule IV – The drug, which is already in Schedule I, is particularly liable to abuse and to produce ill effects, and such liability is not offset by substantial therapeutic advantages.

Schedule I

According to the Commentary, is the category of drugs whose control provisions "constitute the standard regime under the Single Convention." The principal features of that regime are:
  • Limitation to medical and scientific purposes of all phases of narcotics trade in, and of the possession and use of, drugs, except when these drugs are used in industry for other than medical and scientific purposes ;
  • Requirement of governmental authorization of participation in any phase of the narcotics trade and of a specific authorization of each individual international transaction;
  • Obligation of all participants in the narcotics trade to keep detailed records of their transactions in drugs;
  • Requirement of a medical prescription for the supply or dispensation of drugs to individuals;
  • A system of limiting the quantities of drugs available, by manufacture or import or both, in each country and territory, to those needed for medical and scientific purposes.
List of drugs in Schedule I

  • Cannabis, cannabis resin, and extracts and tinctures of cannabis
  • Coca leaf, cocaine and ecgonine:
  • * coca leaves – the leaf of the coca bush, except a leaf from which all ecgonine, cocaine and any other ecgonine alkaloids have been removed
  • * cocaine – an alkaloid found in coca leaves or prepared bionthesis from ecgonine
  • * ecgonine, its esters and derivatives which are convertible to ecgonine and cocaine
  • Natural opiates:
  • * opium – the coagulated juice of the opium poppy, plant species Papaver somniferum L.
  • * concentrate of poppy straw – the material arising when poppy straw has entered into a process for the concentration of its alkaloids when such material is made available in trade
Note on preparations: all preparations made direct from opium are considered to be opium, if the preparations are not made direct from opium itself but are obtained by a mixture of opium alkaloids they should be considered as morphine
Natural opioids:
Semisynthetic opioids:
Some morphine derivatives, including some natural metabolites of morphine and codeine:
Synthetic opioids – morphinan derivatives:
Synthetic opioids – fentanyl and derivatives:
Synthetic 4-phenylpiperidine opioids – pethidines :
Synthetic 4-phenylpiperidine opioids – prodines:
Synthetic 4-phenylpiperidine opioids – ketobemidones:
Synthetic open chain opioids – amidones:
Synthetic open chain opioids – methadols:
Synthetic open chain opioids – moramides:
Synthetic open chain opioids – thiambutenes:
Synthetic open chain opioids – phenalkoxams:
Synthetic open chain opioids – ampromides:
Synthetic opioids – benzimidazoles:
Synthetic opioids – benzomorphans:
Synthetic opioids – pirinitramides:
Synthetic opioids – phenazepanes:
Other synthetic opioids:
And:
  • the isomers, unless specifically excepted, of the drugs in this Schedule whenever the existence of such isomers is possible within the specific chemical designation;
  • the esters and ethers, unless appearing in another Schedule, of the drugs in this Schedule whenever the existence of such esters or ethers is possible;
  • the salts of the drugs listed in this Schedule, including the salts of esters, ethers and isomers as provided above whenever the existence of such salts is possible.
Isomers specifically excluded :

Schedule II

Drugs in Schedule II are regulated only slightly less strictly than Schedule I drugs. The Commentary confirms, "Drugs in Schedule II are subject to the same measures of control as drugs in Schedule I, with only a few exceptions":
  • The drugs are not subject to the provisions of Article 30, paragraphs 2 and 5, as regards the retail trade.
  • Governments are thus not bound to prevent the accumulation of drugs in Schedule II in the possession of retail distributors, in excess of the quantities required for the normal conduct of business.
  • Medical prescriptions for the supply or dispensation of these drugs to individuals are not obligatory.
  • Such drugs are also exempted from the provision – which in fact is no more than a suggestion – concerning the use of official prescription forms in the shape of counterfoil books issued by the competent governmental authorities or by authorized professional associations.
  • Parties to the Single Convention need not require that the label under which a drug in Schedule II is offered for sale in the retail trade show the exact content by weight or percentage.
List of drugs in Schedule II

Natural opioids:
  • codeine – alkaloid contained in opium and poppy straw
Semisynthetic opioids:
Natural codeine metabolite:
Synthetic open chain opioids – phenalkoxams:
Synthetic open chain opioids – ampromides:
And:
  • the isomers, unless specifically excepted, of the drugs in this schedule whenever the existence of such isomers is possible within the specific chemical designation;
  • the salts of the drugs listed in this schedule, including the salts of the isomers as provided above whenever the existence of such salts is possible.

Schedule III

Schedule III "contains preparations which enjoy a privileged position under the Single Convention, i.e. are subject to a less strict regime than other Preparations", according to the Commentary. Specifically:
  • Government authorizations are not required for each import or export of preparations in Schedule III. The import certificate and export authorization system laid down in Article 31, paragraphs 4 to 15, which governs the international transactions in drugs and their preparations, does not apply to the preparations in Schedule III.
  • The only estimates and statistical returns that a Party need furnish to the INCB in reference to Schedule III preparations are estimates of the quantities of drugs to be used for the compounding of preparations in Schedule III, and information on the amounts of drugs actually so used.
List of preparations in Schedule III

Preparations of narcotic drugs exempted from some provisions:
Preparations conforming to any of the formulas listed in this Schedule and mixtures of such preparations with any material which contains no drug.

Schedule IV

This is the category of drugs, such as heroin, that are considered to have "particularly dangerous properties" in comparison to other drugs.
According to Article 2, "The drugs in Schedule IV shall also be included in Schedule I and subject to all measures of control applicable to drugs in the latter Schedule" as well as whatever "special measures of control"; each Party deems necessary. This is in contrast to the U.S. Controlled Substances Act, which has five Schedules ranging from Schedule I to Schedule V, and the Convention on Psychotropic Substances, which has four Schedules ranging for Schedule I to Schedule IV.
Under certain circumstances, Parties are required to limit Schedule IV drugs to research purposes only:
The Commentary explains two situations in which this provision would apply:
The Commentary notes that "Whether the prohibition of drugs in Schedule IV should be mandatory or only recommended was a controversial question at the Plenipotentiary Conference." The provision adopted represents "a compromise which leaves prohibition to the judgement, though theoretically not to the discretion, of each Party." The Parties are required to act in good faith in making this decision, or else they will be in violation of the treaty.
Cannabis and cannabis resin were present in Schedule IV from 1961 until 2 December 2020.
List of drugs in Schedule IV

Semisynthetic opioids:
Synthetic opioids – fentanyl and derivatives:
Synthetic 4-phenylpiperidine opioids – prodines:
Synthetic 4-phenylpiperidine opioids – ketobemidones:
And the salts of the drugs listed in this schedule whenever the formation of such salts is possible.

Limitation of scope

The Single Convention allows only drugs with morphine-like, cocaine-like, and cannabis-like effects to be added to the Schedules. The strength of the drug is not relevant; only the similarity of its effects to the substances already controlled. For instance, etorphine and acetorphine were considered sufficiently morphine-like to fall under the treaty's scope, although they are many times more potent than morphine. However, according to the Commentary:
Since cannabis is a hallucinogen, the Commentary speculates that mescaline, psilocybin, tetrahydrocannabinol, and LSD could have been considered sufficiently cannabis-like to be regulated under the Single Convention; however, it opines, "It appears that the fact that the potent hallucinogenics whose abuse has spread in recent years have not been brought under international narcotics control does not result from legal reasons, but rather from the view of Governments that a regime different from that offered by the Single Convention would be more adequate." That different regime was instituted by the 1971 Convention on Psychotropic Substances. The Convention on Psychotropic Drugs' scope can include any drug not already under international control if the World Health Organization finds that:
  • The substance has the capacity to produce " state of dependence" AND "entral nervous system stimulation or depression, resulting in hallucinations or disturbances in motor function or thinking or behaviour or perception or mood"; or
  • The substance has the capacity to produce similar abuse and similar ill effects as LSD or one of the other controlled substances enumerated in Convention; or
  • There is sufficient evidence that the substance is being or is likely to be abused so as to constitute a public health and social problem warranting the placing of the substance under international control.
The reason for sharply limiting the scope of Single Convention to a few types of drugs while letting the Convention on Psychotropic Drugs cover the rest was concern for the interests of industry. Professor Cindy Fazey's The Mechanics and Dynamics of the UN System for International Drug Control explains, "concerted efforts by drug manufacturing nations and the pharmaceutical industry ensured that the controls on psychotropics in the 1971 treaty were considerably looser than those applied to organic drugs in the Single Convention."
A failed 24 March 2003 European Parliament committee report noted the disparity in how drugs are regulated under the two treaties:
For this reason, the European Parliament, Transnational Radical Party, and other organizations have proposed removing cannabis and other drugs from the Single Convention and scheduling them under the Convention on Psychotropic Substances.

Rescheduling of cannabis

There has long been a controversy over whether cannabis is "particularly liable to abuse and to produce ill effects" and whether that "liability is not offset by substantial therapeutic advantages", as required by Schedule IV criteria. Already in 1973, the Commentary on the Single Convention edited by UN Secretary-General pointed out that "should the results of the intensive research which is at the time of this writing being undertaken on the effects of so warrant, they could be deleted from Schedule IV, and these two drugs, as well as extracts and tinctures of cannabis, could be transferred from Schedule I to Schedule II." Since the discovery of the endocannabinoid receptor system in the late 1980s, which revolutionized the scientific understanding of the psychopharmacological effects of cannabis, and the important progresses in research related to the medical uses of the plant, questions as to the validity of the placement of cannabis and cannabis resin in Schedule IV increased.
In 1991, delta-9-THC was down-scheduled from Schedule I to Schedule II of the Convention on Psychotropic Substances of 1971. After numerous discussions at the World Health Organization in the 2000s and 2010s, on 2 December 2020, the Commission on Narcotic Drugs adopted Decision 63/17 withdrawing "cannabis and cannabis resin" from Schedule IV of the Single Convention. The vote was based on recommendations issued by the World Health Organization in 2019 on the basis of scientific evidence-based reviews. The decision entered into force in April 2021.

Drugs and substances scheduled in other treaties

Cannabinoids and opioids are scheduled by Convention on Psychotropic Substances.
Natural cannabinols :
  • tetrahydrocannabinol, the following isomers and their stereochemical variants:
  • * 7,8,9,10-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzopyran-1-ol
  • * -8,9,10,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzopyran-1-ol
  • * -6a,9,10,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzopyran-1-ol
  • * -6a,7,10,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzopyran-1-ol
  • * 6a,7,8,9-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzopyran-1-ol
  • * -6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-9-methylene-3-pentyl-6H-dibenzopyran-1-ol
  • delta-9-tetrahydrocannabinol – -6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzopyran-1-ol, and its stereochemical variants
Semisynthetic agonist–antagonist opioids:
Synthetic agonist-antagonist opioids – benzomorphans:
Synthetic open chain opioids having also stimulant effects:

Opioids not scheduled

Some opioids currently or formerly used in medicine are not scheduled by UN conventions, for example:
There are of course many opioid designer drugs, not used in medicine.

Governance

The Single Convention gives the UN Economic and Social Council's Commission on Narcotic Drugs power to add or delete drugs from the Schedules, in accordance with the World Health Organization's findings and recommendations. Any Party to the treaty may request an amendment to the Schedules, or request a review of the commission's decision. The Economic and Social Council is the only body that has power to confirm, alter, or reverse the CND's scheduling decisions. The United Nations General Assembly can approve or modify any CND decision, except for scheduling decisions.
The CND's annual meeting serves as a forum for nations to debate drug policy. At the 2005 meeting, France, Germany, the Netherlands, Canada, Australia and Iran rallied in opposition to the UN's zero-tolerance approach in international drug policy. Their appeal was vetoed by the United States, while the United Kingdom delegation remained reticent. Meanwhile, U.S. Office of National Drug Control Policy Director John Walters clashed with United Nations Office on Drugs and Crime Executive Director Antonio Maria Costa on the issue of needle exchange programs. Walters advocated strict prohibition, while Costa opined, "We must not deny these addicts any genuine opportunities to remain HIV-negative."
The International Narcotics Control Board is mandated by Article 9 of the Single Convention to "endeavour to limit the cultivation, production, manufacture and use of drugs to an adequate amount required for medical and scientific purposes, to ensure their availability for such purposes and to prevent illicit cultivation, production and manufacture of, and illicit trafficking in and use of, drugs." The INCB administers the estimate system, which limits each nation's annual production of controlled substances to the estimated amounts needed for medical and scientific purposes.
Article 21 provides that "the total of the quantities of each drug manufactured and imported by any country or territory in any one year shall not exceed the sum of" the quantity:
  • Consumed, within the limit of the relevant estimate, for medical and scientific purposes;
  • Used, within the limit of the relevant estimate, for the manufacture of other drugs, of preparations in Schedule Ill, and of substances not covered by this convention;
  • Exported;
  • Added to the stock for the purpose of bringing that stock up to the level specified in the relevant estimate; and
  • Acquired within the limit of the relevant estimate for special purposes.
Article 21 bis, added to the treaty by a 1971 amendment, gives the INCB more enforcement power by allowing it to deduct from a nation's production quota of opium some or all of the amounts it determines have been produced within that nation and introduced into the illicit traffic. This could happen as a result of failing to control either illicit production or diversion of licitly produced opium to illicit purposes. In this way, the INCB can essentially punish a narcotics-exporting nation that does not control its illicit traffic by imposing an economic sanction on its medicinal narcotics industry.
The Single Convention exerts power even over those nations that have not ratified it. Under Article 12, the International Narcotics Board is mandated to request that governments of countries and territories to which the convention does not apply nevertheless furnish estimates of legitimate needs in accordance with the provisions of the convention. Should they fail to do so, the convention empowers the Board to establish its own estimates for those countries or territories, and the Parties to the convention are obligated to adhere to that estimate in their dealings with that country or territory. Regarding this authority, the International Narcotics Control Board has stated:
Article 14 authorizes the INCB to recommend an embargo on imports and exports of drugs from any noncompliant nations. The INCB can also issue reports critical of noncompliant nations, and forward those reports to all Parties. This happened when the United Kingdom reclassified cannabis from Class B to class C, eliminating the threat of arrest for possession. See Cannabis reclassification in the United Kingdom.
The most controversial decisions of the INCB are those in which it assumes the power to interpret the Single Convention. Germany, the Netherlands, Switzerland, and Spain continue to experiment with medically supervised injection rooms, despite the INCB's objections that the Single Convention's allowance of "scientific purposes" is limited to clinical trials of pharmaceutical grade drugs and not public health interventions. These European nations have more leverage to disregard the Board's decisions because they are not dependent on licit psychoactive drug exports. As international lawyer Bill Bush notes, "Because of the Tasmanian opium poppy industry, Australia is more vulnerable to political pressure than, say, Germany."
The INCB is an outspoken opponent of drug legalization. Its 2002 report rejects a common argument for drug reform, stating, "Persons in favour of legalizing illicit drug use argue that drug abusers should not have their basic rights violated; however, it does not seem to have occurred to those persons that drug abusers themselves violate the basic rights of their own family members and society." The report dismisses concerns that drug control conflicts with principles of limited government and self-determination, arguing, "States have a moral and legal responsibility to protect drug abusers from further self-destruction." The report takes a majoritarian view of the situation, declaring, "Governments must respect the view of the majority of lawful citizens; and those citizens are against illicit drug use."
Article 48 designates the International Court of Justice as the arbiter of disputes about the interpretation or application of the Single Convention, if mediation, negotiation, and other forms of alternative dispute resolution fail.

Related treaties

Previous treaties

The Single Convention was preceded by a series of other international legal instrument, that it terminated and replaced. Article 44 provided that the Single Convention's entry into force terminated several predecessor treaties, including:

Complementary treaties on drug control

The Single Convention is supplemented by two other major drug control treaties:

Other treaties referring to the Single Convention